Curriculum Vitae

** CV must be written in English*

Personal Information

Title (i.e. Pf., Dr., etc.)	**Professor**
Name (First Name/ Middle Name /Last Name)	**Raja Atreya**
Degree (i.e. MD, MSc, PhD, etc.)	**MD**
Country	**Germany**
Affiliation	**Friedrich-Alexander-University Erlangen-Nürnberg University Hospital Erlangen**
E-mail	**raja.atreya@uk-erlangen.de**

Educational Background

1995-2002	Medical School, Johannes Gutenberg University, Mainz
2004	MD (*summa cum laude*), Johannes Gutenberg University, Mainz

Professional Career

Since 2021	Professor for Translational Immunology in IBD, University Hospital Erlangen
Since 2016	Heisenberg Professor for Translational Immunology in IBD, University Hospital Erlangen
Since 2013	Head of the IBD Unit and Outpatient Clinic, University Hospital Erlangen
Since 2012	Head of the Clinical Study Centre, University Hospital Erlangen
2010- 2016	Assistant Professor for Inflammatory Bowel Diseases, University Hospital Erlangen
2010	Resident physician, Department of Internal Medicine 1, University Hospital Erlangen
2007-2009	Postdoctoral Scholarship, PhD-program "Antigen-specific Immunotherapy" (GRK 1043), Department of Internal Medicine 1, Johannes Gutenberg University Mainz
2007	Research group leader, University Hospital Mainz
2004-2007	Resident physician, University Hospital Mainz
2003-2004	Intern physician, University Hospital Mainz

Research Field

Professor Atreya's research work focuses on the identification of response predictors (e.g., molecular endoscopy) and IL23 mediated resistance mechanisms to biological therapies in IBD. He has received many awards in the course of his career including: the Theodor Frerichs Award from the German Society for Internal Medicine; the Paul Ehrlich and Ludwig Darmstaedter Prize for Young Researchers from the Paul Ehrlich Foundation; and the Rising Star Award from the United European Gastroenterology Federation (UEG).

Main Scientific Publications

1. Plechschmidt J, Fietkau K, Hepp T, Dietrich P, Fischer S, Krebs S, Neurath MF, Dörje F, **Atreya R**. Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial. ***Inflamm Bowel Dis***. 2024; 20:izae040. Epub ahead of print.

2. Weber S, Sitte S, Voegele AL, Sologub L, Wilfer A, Rath T, Nägel A, Zundler S, Franchi L, Opipari AW, Sonnewald S, Reid S, Hartmann A, Eichhorn P, Handtrack C, Weber K, Grützmann R, Neufert C, Schellerer VS, Naschberger E, Ekici AB, Büttner C, Neurath MF, **Atreya R**. NLRP3 Inhibition Leads to Impaired Mucosal Fibroblast Function in Patients with Inflammatory Bowel Diseases. ***J Crohns Colitis.*** 2024, 18:446-461.

3. Voskens C, Stoica D, Rosenberg M, Vitali F, Zundler S, Ganslmayer M, Knott H, Wiesinger M, Wunder J, Kummer M, Siegmund B, Schnoy E, Rath T, Hartmann A, Hackstein H, Schuler-Thurner B, Berking C, Schuler G, **Atreya R**[*], Neurath MF*. Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis. ***Gut.*** 2023; 72:49-53. ***Equal contribution.**

4. Schmitt H, Ulmschneider J, Billmeier U, Vieth M, Scarozza P, Sonnewald S, Reid S, Atreya I, Rath T, Zundler S, Langheinrich M, Schüttler J, Hartmann A, Winkler T, Admyre C, Knittel T, Dieterich Johansson C, Zargari A, Neurath MF, **Atreya R.** The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis. ***J Crohns Colitis.*** 2020; 14: 508-524.

5. Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, Hirschmann S, Hildner K, Waldner MJ, Mudter J, Hartmann A, Grützmann R, Neufert C, Münster T, Neurath MF, **Atreya R.** Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease. ***Gut.*** 2019; 68:814-828.

6. **Atreya R**, Neurath MF. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. ***Lancet Gastroenterol Hepatol.*** 2018; 3:790-802.

7. Hess A, Roesch J, Saake M, Sergeeva M, Hirschmann S, Neumann H, Dörfler A, Neurath MF, **Atreya R.** Functional Brain Imaging Reveals Rapid Blockade of Abdominal Pain Response Upon Anti-TNF Therapy in Crohn's Disease. ***Gastroenterology.*** 2015; 149:864-6.

8. **Atreya R**, Neumann H, Neufert C, Waldner MJ, Billmeier U, Zopf Y, Willma M, App C, Münster T, Kessler H, Maas S, Gebhardt B, Heimke-Brinck R, Reuter E, Dörje F, Rau TT, Uter W, Wang TD, Kiesslich R, Vieth M, Hannappel E, Neurath MF. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. ***Nature Medicine*** 2014; 20:313-8.

9. **Atreya R**, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD, Rau TT, Rose-John S, Kessler H, Schmidt J, Neurath MF. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal $CD14^{+}$ macrophages. ***Gastroenterology.*** 2011;141:2026-38.

10. **Atreya R***, Mudter J*, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. ***Nature Medicine*** 2000;6:583-8. ***Equal contribution.**

- Please note that the above information will be used for the introduction of speakers for the IMKASID 2025 website and announcements. Also, it will be provided to the session chairpersons before your lecture.

- Please complete this form (no more than 2 pages) and return it to the IMKASID 2025 secretariat by email, info@imkasid.kr.